Corrigendum to "Investigating the effect of some fluoroquinolones on C-reactive protein levels and ACh-Induced blood pressure reduction deviations after aging of diabetes in STZ-Induced diabetic wistar rats" [Heliyon 6 (4), (April 2020) Article e03812].

[This corrects the article DOI: 10.1016/j.heliyon.

Investigating the effect of some fluoroquinolones on C-reactive protein levels and ACh-Induced blood pressure reduction deviations after aging of diabetes in STZ-Induced diabetic wistar rats.

The treatment of infections in diabetic patients by fluoroquinolone antibiotics is associated with a reduced risk of coronary artery disease, and may improve endothelium-derived hyperpolarizing factor (EDHF) efficacy. The inflammatory marker C-reactive protein (CRP) is an important predictor of cardiovascular events, and vascular endothelium dysfunction, which makes this marker a target for drug-based treatment. This study aims to investigate the relation between the treatment by fluoroquinolones with CRP plasma levels, as well as acetylecholine (ACh)-induced small conductance calcium-activated potassium channels (SK)-dependent blood pressure (BP) reduction deviations in wistar rats after inducing a type 2-like diabetes with aging state after four months of streptozotocin (STZ) injection.